Loading...
Market
What changes will Sarepta Therapeutics make to its gene therapy approach by December 31, 2024?
2
Resolution / Starting Odds
Major changes • 25%
Minor changes • 25%
No changes • 25%
Discontinues gene therapy • 25%
Official announcements or press releases from Sarepta Therapeutics
Story
Sarepta ($SRPT) Faces Backlash for Censoring Critical Duchenne Advocacy Video
Jul 29, 2024, 12:18 PM
Sarepta Therapeutics ($SRPT) has come under scrutiny for demanding a prominent Duchenne muscular dystrophy patient advocacy organization censor a video that contained pointed criticism of its new gene therapy. The video, which was critical of Sarepta's approach and its impact on patients, was subsequently taken down. This incident, reported by STAT, has raised questions about the relationship between drugmakers and patient advocacy groups. The news has sparked discussions about the influence pharmaceutical companies exert over advocacy organizations and the potential implications for patient care and transparency.
View original story
Similar markets
Yes • 50%
No • 50%
Clinical trial initiation • 25%
Regulatory approval • 25%
New program announcement • 25%
No major milestone • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Yes • 50%
No • 50%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
